[1]Querfurth HW, Laferla FM. Mechanisms of disease Alzheimer’s disease[J]. New Engl J Med, 2010, 362(4):329-344. [2]Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration:lessons from the Alzheimer’s amyloid beta-peptide[J]. Nat Rev Mol Cell Bio, 2007, 8(2):101-112. [3]Muller UC, Zheng H. Physiological functions of APP family proteins[J]. Cold Spring Harbor Perspectives in Medicine, 2012, 2(2):a006288. [4]Schneeberger A, Mandler M, Mattner F, et al. AFFITOME(R)technology in neurodegenerative diseases the doubling advantage[J]. Hum Vaccines, 2010, 6(11):948-952. [5]Senior K. Dosing in phase II trial of Alzheimer’s vaccine suspended[J]. Lancet Neurol, 2002, 1(1):3. [6]Pasquier F, Sadowsky C, Holstein A, et al. Two Phase 2 multiple ascending-dose studies of vanutide cridificar(ACC-001)and QS-21 adjuvant in mild-to-moderate Alzheimer’s disease[J]. J Alzheimers Dis, 2016, 51(4):1131-1143. [7]Farlow MR, Andreasen N, Riviere ME, et al. Long-term treatment with active A β immunotherapy with CAD106 in mild Alzheimer’s disease[J]. Alzheimers Res Ther, 2015, 7(1):23. [8]Vandenberghe R, Rinne JO, Boada M, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials[J]. Alzheimers Res Ther, 2016, 8(1):18. [9]Doody RS, Thomas RG, Farlow M, et al. Phase 3 Trials of solanezumab for mild-to-moderate Alzheimer’s disease[J]. New Engl J Med, 2014, 370(4):311-321. [10]Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces A β plaques in Alzheimer’s disease[J]. Nature, 2016, 537(7618):50-56. [11]Relkin N. Clinical Trials of intravenous immunoglobulin for Alzheimer’s disease[J]. J Clin Immunol, 2014, 34(1):S74-S79. [12]Ye S, Zeng R, Jiang P, et al. Concentrations of antibodies against beta-amyloid 40/42 monomer and oligomers in Chinese intravenous immunoglobulins[J]. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138(2):277-282. [13]Boller F, Forbes MM. History of dementia and dementia in history:an overview[J]. J Neurol Sci, 1998, 158(2):125-133. [14]Bleuler E. Dementia praecox or the group of schizophrenias[J]. Vertex, 2010, 21(93):394-400. [15]Alzheimer’s A. 2016 Alzheimer’s disease facts and figures[J]. Alzheimers Dement, 2016, 12(4):459-509. [16]Prince M, Comas-Herrera A, Knapp M, et al. World Alzheimer report 2016:improving healthcare for people living with dementia:coverage, quality and costs now and in the future[C]. London:Alzheimer’s Disease International, 2016. [17] Nimmrich V, Ebert U. Is Alzheimer’s disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid[J]. Rev Neuroscience, 2009, 20(1):1-12. [18] Mandler M, Santic R, Gruber P, et al. Tailoring the antibody respo-nse to aggregated a beta using novel Alzheimer-vaccines[J]. PLoS One, 2015, 10(1):e0115237. [19]Kang C K, Jayasinha V, Martin P T. Identification of peptides that specifically bind A β(1-40)amyloid in vitro and amyloid plaques in Alzheimer’s disease brain using phage display[J]. Neurobiol Dis, 2003, 14(1):146-156. [20]Rasool S, Albay R, Martinez-Coria H, et al. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice[J]. Mol Neurodegener, 2012, 7:37. [21]Goni F, Prelli F, Ji Y, et al. Immunomodulation Targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer’s disease[J]. PLoS One, 2010, 5(10):e13391. |